Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases

Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and efficacy of camrelizumab as neoadjuvant in lung cancer. Here, we present three patients who were diagnosed with IIIA squamou...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Xia, Chunqiu, Liu, Minghui, Liu, Jinghao, Dong, Ming, Zhao, Honglin, Xu, Song, Wang, Dan, Wei, Sen, Song, Zuoqing, Chen, Gang, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514096/
https://www.ncbi.nlm.nih.gov/pubmed/36176413
http://dx.doi.org/10.3389/fonc.2022.843116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514096/
https://www.ncbi.nlm.nih.gov/pubmed/36176413
http://dx.doi.org/10.3389/fonc.2022.843116

Ejemplares similares